Clinical Trial Update: Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial updating on adrenal suppression and pharmacokinetics of Topicort Spray 0.25% in pediatric plaque psoriasis patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Topicort Spray 0.25% (unknown)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Plaque Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2023-03-28